PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC	Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung neoplasm, neoplasm, respiratory tract neoplasm, type 1 diabetes mellitus 12	Not yet recruiting	Phase 2	2026-02-17		NCT07416058

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Guangdong Association of Clinical Trials	20
Qilu Pharmaceutical Co., Ltd.	126

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials